等待開盤 08-01 09:30:00 美东时间
-21.150
-6.00%
今日重点评级关注:古根海姆:维持ProMIS Neurosciences"买入"评级,目标价从35美元升至69美元;BTIG:维持Cullinan Therapeutics"买入"评级,目标价从38美元升至39美元
07-30 11:45
Barclays analyst Tim Long maintains Celestica (NYSE:CLS) with a Overweight and lowers the price target from $441 to $430.
07-29 20:07
Shares of Celestica Inc (NYSE:CLS) rose sharply in pre-market trading after the company posted its second-quarter results, beating analyst estimates on the top and bottom lines. Celestica reported quarterly earnings of $2.54 per share, which beat the Street estimate of $2.30 by 10.43%, according to ...
07-28 17:01